Business News
Community News
COVID News

Regeneron COVID-19 Antibody Cocktail Proves Effective in Clinical Trial

• Bookmarks: 21 • Comments: 1


April 13, 2021

By Rick Pezzullo—

Tarrytown-based Regeneron Pharmaceuticals, Inc.  announced Monday positive data from a Phase 3 trial of recently infected asymptomatic COVID-19 patients evaluating an antibody cocktail.

Advertisement
Rotary Duck Derby in Tarrytown

The study showed REGEN-COV™ (casirivimab with imdevimab) reduced the overall risk of progressing to symptomatic COVID-19 by 31% (primary endpoint), and by 76% after the third day. The trial also demonstrated that REGEN-COV shortened symptom duration and markedly reduced viral levels.

The trial enrolled 204 individuals without any COVID-19 symptoms who tested positive for SARS-CoV-2 but did not have anti-virus antibodies at baseline and were randomized to receive either one dose of REGEN-COV (1,200 mg) or placebo.

“COVID-19 transmission often occurs via infected people who do not yet have symptoms, so it is critical that we rapidly diagnose and treat these individuals for their own health and to prevent transmission,” said Katharine Bar, M.D., co-principal investigator of the trial and Assistant Professor of Medicine, Infectious Diseases, Hospital of the University of Pennsylvania. “These data pave the way for REGEN-COV to be used before patients become symptomatic, with a more convenient subcutaneous administration.”

The trial met all primary and key secondary endpoints. In addition to reducing the risk of symptomatic infections, the total number of weeks patients experienced symptoms was nearly cut in half (45%) with REGEN-COV, and the viral burden was reduced by more than 90%. While not included in the initial analysis plan, researchers also found that no REGEN-COV patients and six placebo patients were either hospitalized or visited the emergency room because of COVID-19 during the 29-day efficacy assessment period.

“These Phase 3 data provide even more evidence that REGEN-COV, this time given to asymptomatic patients via convenient injections, can change the course of COVID-19 infection in non-hospitalized patients,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer at Regeneron. “In this trial, the REGEN-COV antibody cocktail effectively prevented asymptomatic patients from becoming symptomatic, and rapidly lowered their viral load.”

REGEN-COV continues to be evaluated in clinical trials in multiple settings for COVID-19: for the prevention of COVID-19 in household contacts of infected individuals, and in non-hospitalized and certain hospitalized patients, including the open-label RECOVERY trial of hospitalized patients in the UK. As of April 2021, more than 25,000 people have participated in clinical trials involving REGEN-COV.

The development and manufacturing of REGEN-COV have been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response.

Among participants enrolled in the treatment trial, 35% were Latino/Hispanic and 5% were Black/African American. In total, 32% had at least one known factor that put them at high risk of suffering severe consequences from COVID-19.

REGEN-COV is currently available in the U.S. to treat mild-to-moderate COVID-19 in adults, as well as in pediatric patients at least 12 years of age and weighing at least 40 pounds, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization. REGEN-COV has not been approved by the FDA but has been authorized for emergency use.

Share the News!
Advertisement
Andrea Martone - Westchester and Rivertowns Real Estate - Houlihan Lawrence agent

Tarrytown Poised to Close Main Street For Dining On 12 Saturday Nights—And Maybe Approve Parklets

By Barrett Seaman— At their May 17 Board meeting, Tarrytown Trustees are expected to approve the closure of Main Street...
Read More

Playa Bowls Grand Opening Saturday, May 15 in Tarrytown

By Linda Viertel--- “Welcome to Pineapple Land” On Main Street, where customers can enjoy a dizzying variety of superfruit bowls...
Read More

Two Local Students Win National Merit Scholarships

By Rick Pezzullo--- Two local seniors were among 2,500 National Merit Scholarship winners named this week that were chosen from...
Read More

Transfiguration School Students Connect with International Space Station

By Rick Pezzullo--- Middle school students at The Transfiguration School in Tarrytown spoke with astronauts aboard the International Space Station...
Read More

Jazz Forum, Tarrytown Reopens May 28!

After what will have been 446 days of closure due to the pandemic, Jazz Forum Arts will reopen its Jazz...
Read More

New Principal at Sleepy Hollow High School Named

By Rick Pezzullo--- A new principal has been chosen to lead Sleepy Hollow High School. Deborah Brand will succeed Dr....
Read More

Gold Star Mother Margaret J. Horan Memorial Unveiled in Sleepy Hollow

By Rick Pezzullo--- The Margaret J. Horan Gold Star Mothers’ Memorial was unveiled Sunday, May 9th at Horan’s Landing Park...
Read More

Harckham Sponsors Blood Drive in Sleepy Hollow

By Rick Pezzullo--- State Senator Pete Harckham partnered with New York Blood Center (NYBC) Saturday in sponsoring a blood drive...
Read More

COVID-19 Update: Then And Now (It’s Better Now)

By Barrett Seaman— Just three months ago, The Hudson Independent reported that, “All but two or three of the state’s...
Read More
21 recommended
1 notes
773 views
bookmark icon

Write a comment...

Your email address will not be published. Required fields are marked *